Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Second Line Treatment Decision as Per Standard of Care or Foundation Medicine in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer.

Cancer medicine - 1 Apr 2026

Rojo Federico, Felip Enriqueta, Juan Vidal Oscar, García Campelo Rosario, Aguiar Bujanda David, Terrasa Pons Josefa, López-Castro Rafael, Calles Antonio, Paredes Lario Alfredo, Bernabé Caro Reyes, Barneto Aranda Isidoro, García-Palacios Luis, De Castro Carpeño Javier

Abstract excerpt

BACKGROUND: Molecular genetic profiling is crucial for treatment choice in patients with advanced non-small cell lung cancer (NSCLC). The Lung-ONE study aimed to determine the clinical utility of comprehensive genomic profile (CGP) tests, such as FoundationOne CDx or FoundationOne Liquid, in guiding second line therapy decisions for advanced NSCLC patients in Spain. Additionally, the study sought to describe the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to Clinical Decision-Making

Share to ErbB Receptors

Share to Lung Neoplasms

Share to Mutation

Source

Open in PubMed Open full text

Identifiers

PMID: 41968649
DOI: 10.1002/cam4.71790
PMCID: PMC13071178

Genes

ALK
EGFR
BRAF
ERBB2
MET
RET

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Second Line Treatment Decision as Per Standard of Care or Foundation Medicine in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer.PMID 41968649Read ↗

Clinical Utility of Comprehensive Genomic Profiling for Advanced Non-Small Cell Lung Cancer: A Single-Center Retrospective Study.Semantic proximity Read ↗

Actionable NSCLC Mutation Identification by Comprehensive Genomic Profiling for Clinical Trial Enrollment: The European Program for the Routine Testing of Patients With Advanced Lung Cancer (EPROPA).Semantic proximity Read ↗

Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT).Semantic proximity Read ↗

Improving the turnaround time of molecular profiling for advanced non-small cell lung cancer: Outcome of a new algorithm integrating multiple approaches.Semantic proximity Read ↗

Relevance and Effectiveness of Molecular Tumor Board Recommendations for Patients With Non–Small-Cell Lung Cancer With Rare or Complex Mutational ProfilesSemantic proximity Read ↗

Utility of comprehensive genomic profiling in directing treatment and improving patient outcomes in advanced non-small cell lung cancer.Semantic proximity Read ↗

Biomarker Testing for Actionable Alterations in NSCLC-Perspectives from US-Based Academic and Community Oncologists: A Podcast.Semantic proximity Read ↗

American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy.Semantic proximity Read ↗

Dealing with NSCLC EGFR mutation testing and treatment: A comprehensive review with an Italian real-world perspective.Semantic proximity Read ↗

Mutation-tailored treatment selection in non-small cell lung cancer patients in daily clinical practice.Semantic proximity Read ↗

Molecular characterization of non-small cell lung cancer tumors in Latin American patients from Brazil, Chile and Peru uncovers novel potentially driver mutationsSemantic proximity Read ↗

Clinical utility of comprehensive genomic profiling in non-small cell lung cancer: An analysis of a nation-wide database.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.